Prevalence of Steatotic Liver Disease with Fibrosis and Diagnostic Screening Tools in Patients with Psoriasis
DOI:
https://doi.org/10.2340/actadv.v106.44445Keywords:
psoriatic disease, inflammatory skin disease, comorbidities, fatty liver disease, NAFLD, biomarkersAbstract
The prevalence of steatotic liver disease (SLD) with fibrosis in patients with psoriasis is unknown and no consensus on screening exists. Therefore, patients from The Copenhagen Translational Skin Immunology Biobank and Research Programme (BIOSKIN) were examined. SLD was defined as controlled attenuation parameter (CAP) > 250 dB/m and fibrosis as median liver stiffness measurement (LSM) ≥ 8 kPa using transient elastography. Biomarkers included fibrosis-4 index (FIB-4), N-terminal propeptide of collagen (type III), and enhanced liver fibrosis (ELF) test. A total of 403 patients (median age 51 years, 54% men, median BMI 27), 80% with moderate-to-severe psoriasis were enrolled. Based on the transient elastography, 40% of the patients had steatosis (mean CAP 245, ± 55 dB/m) and 5% had fibrosis (median LSM 4.8 kPa, IQR 3.8–5.8). According to self-reported alcohol consumption, all patients with steatosis except for 2 were categorized as having metabolic dysfunction-associated steatotic liver disease (MASLD). With transient elastography as the reference, FIB-4 and ELF had better diagnostic accuracy than PIIINP with Area Under the Receiver Operating Characteristic Curve (AUROC) of 0.92 (95% confidence interval 0.87–0.97) for FIB-4, 0.90 (0.83–0.97) for ELF test, and 0.77 (0.66–0.87) for PIIINP.
Downloads
References
Hutter RVP, Shipkey FH, Tan CTC, Murphy ML, Chowdhury M. Hepatic fibrosis in children with acute leukemia: a complication of therapy. Cancer 1960; 13: 288–307. DOI: https://doi.org/10.1002/1097-0142(196003/04)13:2<288::AID-CNCR2820130213>3.0.CO;2-L
Dahl MGC, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients with psoriasis. Br Med J 1971; 1: 625–630. DOI: https://doi.org/10.1136/bmj.1.5750.625
Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol 2014; 171: 17–29. DOI: https://doi.org/10.1111/bjd.12941
Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest 2022; 45: 1277–1288. DOI: https://doi.org/10.1007/s40618-022-01755-0
Rinella ME, Lazarus JV., Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542–1556. DOI: https://doi.org/10.1097/HEP.0000000000000696
Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54. DOI: https://doi.org/10.1038/nutd.2012.26
Budu-Aggrey A, Brumpton B, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, et al. Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study. PLoS Med 2019; 16: e1002739. DOI: https://doi.org/10.1371/journal.pmed.1002739
Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci 2016; 17: 217. DOI: https://doi.org/10.3390/ijms17020217
Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc 2015; 90: 1233–1246. DOI: https://doi.org/10.1016/j.mayocp.2015.06.013
Gelfand JM, Wan J, Zhang H, Shin DB, Ogdie A, Syed MN, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study. J Am Acad Dermatol 2021; 84: 1636–1643. DOI: https://doi.org/10.1016/j.jaad.2021.02.019
Raahimi MM, Livesey A, Hamilton J, Shipman AR, Aspinall RJ. Liver fibrosis for the dermatologist: a review. Clin Exp Dermatol 2023; 48: 303–309. DOI: https://doi.org/10.1093/ced/llac083
Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 2016; 175: 23–44. DOI: https://doi.org/10.1111/bjd.14816
Raaby L, Zachariae C, Østensen M, Heickendorff L, Thielsen P, Grønbæk H, et al. Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a Danish expert meeting. Acta Derm Venereol 2017; 97: 426–432. DOI: https://doi.org/10.2340/00015555-2599
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020; 82: 1445–1486. DOI: https://doi.org/10.1016/j.jaad.2020.02.044
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461–2498. DOI: https://doi.org/10.1111/jdv.16915
Løvendorf MB, Johansen JD, Skov L. BIOSKIN: a protocol for the Copenhagen Translational Skin Immunology Biobank and Research Programme. BMJ Open 2024; 14: e077207. DOI: https://doi.org/10.1136/bmjopen-2023-077207
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457. DOI: https://doi.org/10.1016/S0140-6736(07)61602-X
Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659–689. DOI: https://doi.org/10.1016/j.jhep.2021.05.025
Perilli M, Toselli F, Franceschetto L, Cinquetti A, Ceretta A, Cecchetto G, et al. Phosphatidylethanol (PEth) in blood as a marker of unhealthy alcohol use: a systematic review with novel molecular insights. Int J Mol Sci 2023; 24: 12175. DOI: https://doi.org/10.3390/ijms241512175
Helander A, Hansson T. The alcohol biomarker phosphatidylethanol (PEth)-test performance and experiences from routine analysis and external quality assessment. Scand J Clin Lab Invest 2023; 83: 424–431. DOI: https://doi.org/10.1080/00365513.2023.2253734
Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 2020; 73: 252–262. DOI: https://doi.org/10.1016/j.jhep.2020.03.036
Xu X, Jin J, Liu Y. Performance of FibroScan in grading steatosis and fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Arab J Gastroenterol 2023; 24: 189–197. DOI: https://doi.org/10.1016/j.ajg.2023.08.003
Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023; 8: 20–30. DOI: https://doi.org/10.1016/S2468-1253(22)00317-X
Ginès P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, et al. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology 2022; 75: 219–228. DOI: https://doi.org/10.1002/hep.32163
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015; 45: 156–162. DOI: https://doi.org/10.1016/j.semarthrit.2015.05.003
Atallah E, Grove JI, Crooks C, Burden-Teh E, Abhishek A, Moreea S, et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol 2023; 78: 989–997. DOI: https://doi.org/10.1016/j.jhep.2022.12.034
Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2022; 22: 429–443. DOI: https://doi.org/10.1038/s41577-021-00639-3
González Fernández J, Prieto-Torres L, Ara Martín M, Martínez-Domínguez SJ. MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review. Therap Adv Gastroenterol 2025; 18. DOI: https://doi.org/10.1177/17562848251335824
Maybury CM, Samarasekera E, Douiri A, Barker JN, Smith CH. Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. Br J Dermatol 2014; 170: 1237–1247. DOI: https://doi.org/10.1111/bjd.12905
Zachariae H, Muhammad Aslam H, Bjerring P, Søgaard H, Zachariae E, Heickendorff L. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25: 50–53. DOI: https://doi.org/10.1016/0190-9622(91)70173-Y
Crofton PM, Wade JC, Taylor MRH, Holland CV. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem 1997; 43: 1577–1581. DOI: https://doi.org/10.1093/clinchem/43.9.1577
Sharma C, Cococcia S, Ellis N, Parkes J, Rosenberg W. Systematic review: accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. J Gastroenterol Hepatol 2021; 36: 1788–1802. DOI: https://doi.org/10.1111/jgh.15482
van der Voort EAM, Wakkee M, Veldt-Kok P, Darwish Murad S, Nijsten T. Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). Br J Dermatol 2017; 176: 1599–1606. DOI: https://doi.org/10.1111/bjd.15220
McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017; 112: 740–751. DOI: https://doi.org/10.1038/ajg.2016.453
Martyn-Simmons CL, Rosenberg WMC, Cross R, Wong T, Smith CH, Barker JNWN. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. Br J Dermatol 2014; 171: 267–273. DOI: https://doi.org/10.1111/bjd.12782
Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol 2023; 79: 277–286. DOI: https://doi.org/10.1016/j.jhep.2023.04.002
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Charlotte Näslund-Koch, Marianne B. Løvendorf , Helene M. Martin, Mila B. Johansen, Morten B. Trelle, Claus Zachariae , Lise L. Gluud, Lone Skov
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
